The University of New Mexico Comprehensive Cancer Center is expanding its clinical space to offer treatments that no other entity in the state can offer.
Dr. Aditya Bardia, a renowned breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, has joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center where he will assume several leadership roles across the institution.
Inaugural chief health artificial intelligence officer joins UC San Diego Health.
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored a follow-up analysis of patient-reported outcomes (PROs) that evaluated outcomes three years after initiation of dupilumab among adults with atopic dermatitis (AD).
For thousands of people around the world waiting for a kidney, paired exchange serves as a beacon of hope. One person's willingness to undergo the act of Kidney Paired Donation (KPD) often sets in motion a chain of beautiful and selfless acts, where individuals give and receive the chance for a better life.
Baylor Scott & White Heart and Vascular Hospital – Dallas has added an innovative, minimally invasive option for patients with hypertension, or high blood pressure.
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities. That’s the conclusion of a five-year analysis of results from the U.S. Lymphoma CAR-T Cell Consortium.
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
A new study from researchers with Sylvester Comprehensive Cancer Center and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.
Can AI save us from the arduous and time-consuming task of academic research collection? An international team of researchers investigated the credibility and efficiency of generative AI as an information-gathering tool in the medical field.
Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.
Memorial Hermann Health System President & CEO, Dr. David Callender, was named one of the 100 Most Influential People in Healthcare by Modern Healthcare.
20221027104337.jpg&width=400&height=400)
The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
The holiday season should be a time for families to come together, even when illness lands a loved one in the hospital.
A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union.
The FDA agreed to require important American Academy of Dermatology’s (AAD) recommended changes to the iPLEDGE program that will alleviate administrative burdens for dermatologists.
The academic medical center is one of only 74 "Top Teaching Hospitals" on the 2023 list, which highlights nationally recognized achievements in patient safety and quality.
The Leapfrog Group, a national hospital watchdog organization, has named USC Norris Cancer Hospital a 2023 Top Teaching Hospital.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right